Unique ID issued by UMIN | UMIN000052895 |
---|---|
Receipt number | R000060355 |
Scientific Title | Non-interventional prospective observational study: changes in hepatic profile with standard treatment of hypertriglyceridemia-associated MASLD |
Date of disclosure of the study information | 2023/11/24 |
Last modified on | 2023/11/24 18:14:22 |
Non-interventional prospective observational study: changes in hepatic profile with standard treatment of hypertriglyceridemia-associated MASLD
Non-interventional prospective observational study: changes in hepatic profile with standard treatment of hypertriglyceridemia-associated MASLD
Non-interventional prospective observational study: changes in hepatic profile with standard treatment of hypertriglyceridemia-associated MASLD
Non-interventional prospective observational study: changes in hepatic profile with standard treatment of hypertriglyceridemia-associated MASLD
Japan |
Hypertriglyceridemia complicated MASLD
Medicine in general | Hepato-biliary-pancreatic medicine | Endocrinology and Metabolism |
Others
NO
The objective is to prospectively identify clinical markers and hepatic pathological changes in hypertriglyceridemia-associated MASLD as affected by the current standard treatment of hypertriglyceridemia: diet, exercise, and fibrate therapy.
Others
The objective is to prospectively identify changes in liver signaling pathways in hypertriglyceridemia-associated MASLD as affected by current standard therapy.
Changes in liver histology (fibrosis stage and NAS) from time of enrollment to 52 weeks or later.
Percentage and amount of change in laboratory values from enrollment to 52 weeks or later (TG, TC, HDL-C, LDL-C (direct method), WBC, RBC, Hb, Plt, PT%, TP, Alb, BUN, Cre, eGFR, Na, K, Cl, T-Bil, D-Bil, I-Bil, AST, ALT, AFP, AFP- L3, PIVKA-II, type 4 C7S, M2BPGi, Autotaxin, etc.),Changes in imaging findings from enrollment to 52 weeks or later: CT values, MRI (PDFF values, elastography values) US (presence of fatty liver), Fibroscan (CAP values, E values),Changes in body composition from the time of enrollment to 52 weeks or later: InBody,Liver signaling pathway (Single-nucleus RNA-seq analysis, Quantitative PCR, Western blotting, immunohistochemistry),Adverse events.
Observational
20 | years-old | <= |
80 | years-old | > |
Male and Female
Hypertriglyceridemic patients between the ages of 20 and 80 years who have been diagnosed with MASLD by the NASH Clinical Research Network classification on liver biopsy and whose disease status will be evaluated by multiple liver biopsies.
Patients who meet the above criteria and have started standard treatment (diet, exercise, and fibrate therapy).
Cases in which written consent to participate in the study cannot be obtained.
30
1st name | Takeji |
Middle name | |
Last name | Umemura |
Shinshu University
Gastroenterology
390-8621
3-1-1 Asahi, Matsumoto City, Nagano Prefecture
81263372644
t-umemura@shinshu-u.ac.jp
1st name | Takefumi |
Middle name | |
Last name | Kimura |
Shinshu University
Gastroenterology
3908621
3-1-1 Asahi, Matsumoto City, Nagano Prefecture
81263372644
t_kimura@shinshu-u.ac.jp
Shinshu University
Others
Other
Japan
Shinshu University School of Medicine Ethics Committee
3-1-1 Asahi-, Matsumoto City, Nagano Prefecture
81263372644
t_kimura@shinshu-u.ac.jp
NO
2023 | Year | 11 | Month | 24 | Day |
Unpublished
Enrolling by invitation
2023 | Year | 11 | Month | 14 | Day |
2023 | Year | 11 | Month | 14 | Day |
2023 | Year | 11 | Month | 24 | Day |
2028 | Year | 03 | Month | 31 | Day |
Conducted at Shinshu University.
2023 | Year | 11 | Month | 24 | Day |
2023 | Year | 11 | Month | 24 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000060355